Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung ...
With thousands of companies and a $102 billion impact on the state’s economy, Indiana’s life sciences industry is making its ...
While RA Capital Management has yet to commit to a merger plan, it noted that its new blank-check company, Research Alliance ...
Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like ...
In vivo CAR-T has attracted significant attention from venture capital and the pharmaceutical industry. By offering the ...
This year's catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill.
Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval ...
Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, ...
Draft guidance, issued by the FDA last week, could remove ambiguity and uncertainty that may have so far limited uptake of ...
Trace Neuroscience, a member of BioSpace’s NextGen Class of 2026, has learned from the success of Biogen’s Qalsody and aims ...
Gilead’s median employee compensation in 2025 was $238,979. Daniel O’Day’s compensation package is 119 times larger.
The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results